Pancreatic Cancer New Treatment 2026: Daraxonrasib
Decision brief
Answer first · skim in under a minute
Pancreatic cancer new treatment 2026 conversations now center on daraxonrasib, an oral RAS(ON) multi-selective inhibitor. In Phase 3 RASolute 302, median overall survival nearly doubled versus investigator-choice chemotherapy in previously treated metastatic PDAC.
Pancreatic cancer new treatment 2026 conversations now center on daraxonrasib, an oral RAS(ON) multi-selective inhibitor. In Phase 3 RASolute 302, median overall survival nearly doubled versus investigator-choice chemotherapy in previously treated metastatic PDAC.
Contents11 sections
Key Takeaways
- RASolute 302 (NCT06625320) randomized previously treated metastatic PDAC patients to oral daraxonrasib 300 mg once daily or investigator-choice chemotherapy.
- In the intent-to-treat population, median OS was 13.2 months with daraxonrasib versus 6.7 months with chemo (HR 0.40; p<0.0001).
- Results were detailed in a GlobeNewswire ASCO plenary release and published in the New England Journal of Medicine / PubMed record.
- Daraxonrasib is not FDA-approved yet; Revolution Medicines has discussed global filings including a U.S. NDA path.
What did RASolute 302 show for pancreatic cancer survival?
Revolution Medicines’ 13 April 2026 GlobeNewswire topline reported median OS of 13.2 versus 6.7 months (HR 0.40; p<0.0001) for daraxonrasib versus chemo in the ITT population.
The registrational study is listed as NCT06625320. Dual primary endpoints focus on PFS and OS in the RAS G12 population, with secondary analyses in all-comers.
How does daraxonrasib differ from G12C-only drugs?
Approved KRAS G12C inhibitors cover a rare slice of PDAC. Daraxonrasib is designed as a multi-selective RAS(ON) inhibitor spanning common G12D/V/R variants that drive most pancreatic tumors. That breadth is why BD teams map it as a potential second-line backbone if regulators accept the Phase 3 package.
Which efficacy numbers belong in a diligence model?
ASCO plenary detail on GlobeNewswire (31 May 2026) and the PubMed/NEJM report reinforce ITT OS 13.2 vs 6.7 months and RAS G12 OS 13.2 vs 6.6 months, both HR 0.40.
- Dose: 300 mg oral once daily
- Comparator: investigator-choice IV chemo regimens
- Enrollment: about 500 patients
- RAS G12 share: ~91.8% in the published cohort summary
What is the regulatory status today?
Daraxonrasib remains investigational. PubMed indexes the Phase 3 publication as PMID 42223072. Company communications discuss NDA planning and prior FDA designations; confirm live FDA designation letters before calling anything “approved.”
Competitive implications for pancreatic cancer franchises
If approved, an oral multi-RAS inhibitor with a halved death risk versus chemo would pressure second-line chemo share and reshape combo strategies with immunotherapy or chemotherapy backbones. Watch first-line and NSCLC expansion programs as separate value nodes.
What remains unproven?
Overall survival in earlier lines, brain-penetrance claims, and long-term resistance patterns are not settled by RASolute 302 alone. Safety is described as manageable with no new signals in topline copy, but full adverse-event tables still need label-level review.
BD checklist after the ASCO plenary
Update peak-sales models with HR 0.40 OS, flag filing timing risk, and separate PDAC second-line value from broader RAS franchise optionality. Keep GlobeNewswire + ClinicalTrials.gov + PubMed as the citation triad—not hospital newsroom summaries.
Related NovaPharma coverage
- Revolution Medicines daraxonrasib breakthrough analysis
- Pancreatic cancer disease hub
- FDA gene therapy guidance notes
Frequently Asked Questions
What is daraxonrasib?
Daraxonrasib is an investigational oral RAS(ON) multi-selective inhibitor from Revolution Medicines being developed for RAS-addicted cancers, including previously treated metastatic pancreatic ductal adenocarcinoma.
What did RASolute 302 show for overall survival?
In the intent-to-treat population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with investigator-choice chemotherapy (hazard ratio 0.40; p less than 0.0001).
Is daraxonrasib an approved pancreatic cancer new treatment in 2026?
Not yet. Phase 3 results are public and publications are available, but FDA approval had not been granted as of the sources cited in this article.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for daraxonrasib.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
